Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2026-06-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于聘任及调整高级管理人员的公告
Board/Management Information Classification · 95% confidence The document is an official announcement by the board of directors regarding the appointment and adjustment of senior management personnel (marketing general manager, financial officer, and adjustments of roles). It describes board resolutions on management changes, fitting the definition of a Board/Management Information filing.
2026-06-07 Chinese
独立董事提名人声明与承诺（陈修）
Board/Management Information Classification · 80% confidence The document is a public announcement by 广州市香雪制药股份有限公司 regarding the nomination of an independent director candidate, including detailed statements and commitments about the nominee’s qualifications and compliance with various laws and exchange rules. It is not a financial report, proxy solicitation, or dividend notice, but rather a board-related governance disclosure about director nomination. Therefore, it fits the Board/Management Information category.
2026-06-07 Chinese
关于董事、独立董事离任及补选独立董事并调整董事会专门委员会的公告
Board/Management Information Classification · 95% confidence The document is a formal company announcement detailing the resignation of existing board members and independent directors, the nomination and pending election of a new independent director, and adjustments to board committees. This clearly fits the category for announcements of changes in the board of directors or senior management.
2026-06-07 Chinese
关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice to convene the 2025 Annual General Meeting of Guangzhou Xiangxue Pharmaceutical, detailing meeting date, venues, agenda items, voting methods, and attaching proxy forms and registration instructions. It is sent to shareholders to provide information and solicit votes for the AGM. This matches the definition of a Proxy Solicitation & Information Statement (PSI), rather than an actual report or post‐meeting release.
2026-06-07 Chinese
第九届董事会第三十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is titled “第九届董事会第三十六次会议决议公告” and details resolutions passed by the board of directors, including appointments and adjustments of senior management, nomination and resignation of independent directors, and changes to board committees. This clearly constitutes an announcement of changes in the company’s board and senior management, matching the Board/Management Information category.
2026-06-07 Chinese
独立董事候选人关于参加独立董事培训并取得独立董事资格证书的承诺函
Regulatory Filings Classification · 90% confidence The document is a commitment letter by an independent director nominee attesting to complete required training and obtain the qualification certificate. It does not contain actual financial data, nor is it an AGM presentation, board appointment notice, or proxy material. It is essentially a compliance/attestation letter, so it falls under general Regulatory Filings (RNS).
2026-06-07 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.